Treatment
CAR-T cells clinical trials
We’re tracking 489 recruiting studies that include CAR-T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT07361224RecruitingPhase 1
Combining CLS-015 with CAR-T for large B-cell lymphoma
This trial tests combining an experimental drug (CLS-015) with a standard CAR-T cell therapy for people with large B-cell lymphoma whose disease is stable or progressing. It aims to see if the combination is safe and might improve treatment outcomes.
Tel AvivAges 18 years+ - NCT04914091Recruiting
Study comfort and medication use after CAR-T therapy
This study looks at quality of life and how medicines are used for people who are getting CAR-T cell therapy for DLBCL. It aims to better understand what helps patients feel and function during follow-up after treatment.
Pierre-BéniteAges 18 years+ - NCT05659628RecruitingPhase 1
CD19 CAR-T plus PD-1 antibody for relapsed lymphoma
This Phase 1 study tests a new type of immune cell therapy (CD19 CAR-T) combined with an anti–PD-1 drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It aims to improve cancer control when standard treatments have not worked or the cancer has come back.
Hangzhou, ZhejiangAges 18–75 - NCT07441291RecruitingPhase 3
CAR-T vs donor immune cells for residual leukemia after transplant
This study tests whether a therapy using your own immune cells (CAR-T) works better than donor immune cells (DLI) to remove leftover leukemia cells after a stem cell transplant. The goal is to prevent the leukemia from coming back.
Beijing, ChinaAges 3–79 - NCT06834529RecruitingPhase 1/Phase 2
CAR-T cell therapy for returning B-cell leukemia or lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
Beijing, Beijing MunicipalityAges 14–75 - NCT07162038RecruitingPhase 1
CAR-T cells plus half-matched stem cell transplant for high-risk blood cancer
This trial tests giving special immune cells (CAR-T cells) that target a protein called CD19 on cancer cells, followed by a half-matched stem cell transplant, to treat high-risk blood cancers. The treatment aims to improve outcomes by using the CAR-T cells to reduce disease before the transplant.
Bethesda, MarylandAges 18–75 - NCT07594496Enrolling by invitation
Cannabis Withdrawal in Blood Cancer Patients During Stem Cell Transplant
This study looks at whether patients with blood cancers who use cannabis experience withdrawal symptoms when hospitalized for stem cell transplant or CAR-T therapy (a type of immunotherapy). Understanding these symptoms could help doctors better support patients during treatment.
Scottsdale, ArizonaAges 18 years+ - NCT06976437RecruitingEarly Phase 1
Testing donor CAR-T cells for B-cell blood cancers
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
Zhenjiang, JiangsuAges 18 years+ - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT04107285Recruiting
Study brain changes in people with lymphoma after CAR T
This study looks at how thinking and brain function change over time in people with lymphoma who receive CAR T therapy. It may help doctors understand side effects and better support patients during and after treatment.
New York, New YorkAges 18 years+ - NCT07627711RecruitingPhase 1/Phase 2
CAR-NK cells for advanced pancreatic cancer
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT07480928RecruitingPhase 1/Phase 2
CAR-NK cell therapy for advanced pancreatic cancer
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT06706102RecruitingPhase 4
Study of Tiny Blood Particles During CAR-T Therapy
This study is for people getting CAR-T cell therapy, a type of cancer treatment that uses your own immune cells. Researchers want to understand a rare side effect called neurotoxicity by looking at tiny particles in your blood called extracellular vesicles.
Saint-EtienneAges 18 years+ - NCT06691152RecruitingPhase 1
CD19 UCAR T cells for severe lupus
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT07390071Recruiting
Remote rehab program for CAR-T cell therapy patients
This trial tests a home-based rehabilitation program using phone or video sessions to help people with lymphoma or myeloma recover better after CAR-T cell therapy. It aims to improve physical function and quality of life during treatment.
Salt Lake City, UtahAges 21 years+ - NCT06836505RecruitingPhase 1/Phase 2
CAR-T cell therapy for relapsed neuroblastoma and related tumors
This trial tests a new immune cell therapy (CAR-T) for people whose neuroblastoma or desmoplastic small round cell tumor has returned or not responded to standard treatments. The goal is to see if this therapy is safe and can help shrink or control the cancer.
Guangzhou, GuangdongAges 1–50 - NCT07248163Recruiting
Universal CAR-T cell therapy for non-Hodgkin lymphoma
This trial tests a universal CAR-T cell therapy for patients with non-Hodgkin lymphoma whose cancer cells have CD19 on their surface. It might help if standard treatments have not worked.
ShanghaiAges 18 years+ - NCT06904131Recruiting
CAR-T cell therapy for advanced gynecological cancers
This trial tests a new type of immunotherapy called CAR-T cells for advanced ovarian, uterine, or other gynecological cancers that have not responded to standard treatments. The CAR-T cells are specially designed to target proteins (MUC1, MSLN, PD-L1) found on cancer cells.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05741359RecruitingPhase 1
Study of BRL-201 for hard-to-treat aggressive B-cell lymphoma
This Phase 1 study tests BRL-201 (an anti-CD19 treatment) for safety and early signs of effectiveness in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It may help people whose lymphoma has returned or not responded to prior treatments.
Wuhan, HubeiAges 18 years+ - NCT05077527RecruitingPhase 1
CAR-T treatment for HIV and aggressive B-cell lymphoma
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Duarte, CaliforniaAges 18 years+ - NCT07008885RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed/refractory B-ALL
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
Beijing, Biotherapeutic Department of Chinese PLA General HospitalAges 18–70 - NCT06961669Recruiting
CD19 CAR-T cells for B-cell cancers and multiple myeloma
This trial tests a personalized treatment where your own immune cells are modified to target and kill cancer cells that have a protein called CD19. It is for patients with certain types of B-cell lymphoma, B-cell acute leukemia, or multiple myeloma that has come back or not responded to previous treatment.
HefeiAges 3 years+ - NCT06464861RecruitingPhase 1
Sequential CD19 CAR-NK and CAR-T for B-cell lymphoma
This trial tests a new combination treatment: first, natural killer cells (NK cells) that are engineered to find CD19, followed by CAR-T cells (also targeting CD19). It is for people with B-cell lymphoma that has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06585514RecruitingPhase 1/Phase 2
CAR T-cell therapy for hard-to-treat lupus
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
Beijing, Beijing MunicipalityAges 3–65
Common questions
- Are there clinical trials studying CAR-T cells?
- Yes. Clin2 currently lists 489 recruiting studies that include CAR-T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CAR-T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CAR-T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CAR-T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.